Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

• Status: Recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Low radiation doses produce anti-inflammatory effects, which may be useful in the treatment of respiratory complications of COVID-19. This type of treatment is non-invasive and therefore, a priori, it can be used in all types of patients.

Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to the pre baseline measurement. -irradiation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grupo de Investigación Clínica en Oncología Radioterapia
• Collaborators: Hospital del Mar; Hospital Universitari Sant Joan de Reus; Hospital Universitario Madrid Sanchinarro
• Treatments: Azithromycin; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Hydroxychloroquine; Lopinavir; Ritonavir; Tinzaparin

Criteria

Inclusion Criteria:

• Age >=18 years old

• Moderate to severe COVID-19 pneumonia with fewer than 8 days of symptom onset and currently receiving standard medication for COVID-19 at appropriate doses

• PAFIO2 of less than 300 mmHg or SaFI02 <315 mmHg

• Patients who are not candidates for admission to the Intensive Care Unit due to age, concomitant diseases or general condition.

• One of the following conditions:

• or IL6 greater than 40

• or PCR> 100mg / l

• D-dimer greater than 1500ng / ml

• Suspected cytokine release syndrome

• Have read the information sheet and signed the informed consent

Exclusion Criteria:

• Age <18 years

• Failure to meet the inclusion criteria

• Leukopenia <1000

• Pregnancy

• Not understanding or refusing the purpose of the study